Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Agreement to Advance Novel Oral Immuno-Oncology Drug Candidate

Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Agreement to Advance Novel Oral Immuno-Oncology Drug Candidate

Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced today a strategic and exclusive collaboration with Takeda to develop and commercialize a novel immuno-oncology small molecule inhibitor as a mono- and/or combination-therapy. Under the terms of the agreement, Kumquat granted Takeda an exclusive, global, and royalty bearing license to develop and commercialize … Read more